Clinical trials: Cardiovascular Condition
Hemorrhoids
Effectiveness & Safety of Neofitoroid® in Hemorrhoidal Disease
Evaluation of the effect and safety of NeoFitoroid® in reducing symptoms in patients with hemorrhoidal disease.
- Trial name
- NCT03545724
- Testing
- Neofitoroid®
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Aboca Spa Societa' Agricola
Hypertension
Nutraceutical Supplement in the Management of Hypertension
The purpose of this study is to evaluate the efficacy and safety of a proprietary nutraceutical supplement in capsule form over 4 months in treating blood pressure in a group of chronic hypertensive subjects that are not…
- Trial name
- NCT02663479
- Testing
- Cardiopressin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Thorne HealthTech, Inc
Carcinoma, Midline
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
This study is divided into two parts; Part 1 of the study is a dose escalation phase to select the recommended dose for Part 2 based on the safety, pharmacokinetic, and pharmacodynamic profiles observed after oral administration…
- Trial name
- NCT01587703
- Testing
- GSK525762
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017
This study aims to describe the prevalence of type 2 diabetes mellitus (T2DM) patients with established cardiovascular disease (CVD) according to the (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus…
- Trial name
- NCT04927858
- Testing
- Empagliflozin
- Where
- Sweden
- Volunteers
- 460,558 people
- Sponsor
- Boehringer Ingelheim
Multiple Myeloma
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
This study will find the highest acceptable treatment dose and timing of infusion of cord blood, culture expanded natural killer (NK) cells, a kind of immune cell, in patients with multiple myeloma.
- Trial name
- NCT02955550
- Testing
- rhIL-2, PNK-007
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celularity Incorporated
Peripheral Artery Diseases
Detour2 Continued Access Study
Prospective, single-arm, multi-center, clinical investigation to continue to evaluate the safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant stent grafts for a percutaneous femoropopliteal…
- Trial name
- NCT04625660
- Testing
- PQ Bypass System
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Endologix
Hypertension
A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension
A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan (BR-A-657·K) 30mg Compared to Placebo in Patients with Mild to Moderate Essential Hypertension
- Trial name
- fimasartan (NCT01672476)
- Testing
- Valsartan, Fimasartan
- Where
- South Korea
- Volunteers
- 293 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Stroke, Ischemic
SYNCHRONISE: LVO Triage Timing and Outcome Study
The objective of this study is to evaluate the impact of Viz LVO in hospital systems with non-interventional and interventional (spoke and hub) stroke centers on the timing and outcomes of patients with suspected acute ischemic…
- Trial name
- NCT04608617
- Testing
- Viz LVO (De Novo Number DEN170073), Baseline Effectiveness Cohort
- Where
- 3 sites in United States
- Volunteers
- 600 people
- Sponsor
- Viz.ai, Inc.
Hypertension
Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy
The purpose of this study was to evaluate the effect of celecoxib on the efficacy and safety of amlodipine besylate in subjects with newly diagnosed hypertension requiring antihypertensive therapy.
- Trial name
- NCT02172040
- Testing
- Over-encapsulated 10 mg amlodipine besylate tablet, Over-encapsulated 200 mg celecoxib capsule
- Where
- 10 sites in United Kingdom
- Volunteers
- 152 people
- Sponsor
- Kitov Pharmaceuticals, Ltd.
Magnetic Resonance Angiography, Peripheral Vascular Diseases
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
The objective of the study was to compare the efficacy of Magnevist (SH L 451 A) at doses of 0.1 mmol/kg and 0.2 mmol/kg in contrast-enhanced 3D-Magnetic Resonance Angiography in three regions (abdominal, femoral, and leg…
- Conditions
- Magnetic Resonance Angiography, Peripheral Vascular Diseases, Peripheral Arterial Diseases
- Trial name
- NCT00652418
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
- Where
- 3 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Bayer
Multiple Myeloma
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
The purpose of this original study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in combination with the backbone treatment regimen.
- Trial name
- NCT03984097
- Testing
- TAK-079, Lenalidomide, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Takeda
Pulmonary Hypertension
Discovering Clinical Study Experiences of Patients With Pulmonary Hypertension
Taking part in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
- Trial name
- NCT05918458
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Hypertension
The "Global Paradise System" Registry
The GPS Registry is a multi-centre, single-arm, non-interventional (observational) registry. In addition to collecting data from patients treated as per standard clinical practice, the Registry will also regularly collect…
- Trial name
- GPSRegistry (NCT05027685)
- Testing
- The Paradise Ultrasound Renal Denervation System
- Where
- 55 sites in Austria, Belgium and 7 more
- Volunteers
- 3,000 people
- Sponsor
- ReCor Medical, Inc.
Hypertension, Heart Failure
Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules
Prazosin hydrochloride (HCl) is an oral anti-hypertensive indicated for the treatment of primary and secondary hypertension and heart failure. Pfizer Inc.
- Trial name
- NCT04967443
- Testing
- Prazosin HCl 2mg, Prazosin HCl 1 mg, Prazosin HCl 5 mg
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Pfizer
Peripheral Arterial Disease
The Isthmus Logic Post Market Clinical Follow-up Study
Isthmus Logic Carbostent™ is a CE-marked cobalt chromium stent with a bio inducer surface for the treatment of peripheral iliac artery disease.
- Trial name
- NCT05616143
- Testing
- Isthmus Logic
- Where
- Italy
- Volunteers
- 37 people
- Sponsor
- CID S.p.A.
Cardiac Disease
Health App Data Collection Study
Utilization of additional wearable data to improve clinical outcome
- Trial name
- NCT06595615
- Testing
- cardiovascular implantable electronic devices
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Abbott Medical Devices
Multiple Myeloma
Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of a consolidation therapy with bortezomib in patients with multiple myeloma aged 61 to 75.
- Trial name
- NCT00416208
- Testing
- Bortezomib
- Where
- 37 sites in Germany
- Volunteers
- 154 people
- Sponsor
- Janssen-Cilag G.m.b.H
Waldenstrom Macroglobulinemia
A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
The purpose of this study is to evaluate the efficacy of ibrutinib based on overall response rate (ORR) (partial response [PR] or better) by investigator assessment per the modified Consensus Response Criteria from the Sixth…
- Trial name
- NCT04042376
- Testing
- Ibrutinib
- Where
- 6 sites in China
- Volunteers
- 17 people
- Sponsor
- Janssen Research & Development, LLC
Essential Hypertension
Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension
This study is to determine the change in blood pressure from the administration of Olmesartan/Amlodipine/Hydrochlorothiazide triple combinations compared to dual combinations with Olmesartan/Amlodipine.
- Trial name
- NCT00923091
- Testing
- olmesartan medoxomil + amlodipine + hydroclororthiazide, olmesartan medoxomil + amlodipine
- Where
- 133 sites in Belgium, Bulgaria and 13 more
- Volunteers
- 2,689 people
- Sponsor
- Daiichi Sankyo
Multiple Myeloma
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
- Trial name
- MonumenTAL-2 (NCT05050097)
- Testing
- Talquetamab, Carfilzomib, Daratumumab SC
- Where
- 31 sites in United States, Australia and 4 more
- Volunteers
- 166 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.